Are you Dr. Bajaj?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 26 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
9500 Euclid Ave
# A-53
Cleveland, OH 44195Phone+1 216-445-0682Fax+1 216-445-1656
Summary
- Dr. Harpreet Bajaj, MD is an endocrinologist in Cleveland, Ohio.
Education & Training
Hennepin HealthcareResidency, Internal Medicine, 2004 - 2007
Maulana Azad Medical CollegeClass of 2001
Clinical Trials
- Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria Start of enrollment: 2013 Oct 01
- Randomized Trial Comparing Colesevelam vs. Ezetimibe Start of enrollment: 2016 Jan 11
- The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians Start of enrollment: 2018 Oct 02
Publications & Presentations
PubMed
- 5 citationsRandomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Ori...Harpreet S Bajaj, Lisa Chu, Nandini Bansal, Ruth E Brown, Gagandeep Dhillon
Canadian Journal of Diabetes. 2022-07-01 - 3 citationsImpact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLU...Thomas R. Pieber, Harpreet S. Bajaj, Simon Heller, Ting Jia, Kamlesh Khunti
Diabetes, Obesity & Metabolism. 2021-10-17 - 68 citationsEfficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.Juan P. Frias, Pernille Auerbach, Harpreet S. Bajaj, Yasushi Fukushima, Ildiko Lingvay
The Lancet. Diabetes & Endocrinology. 2021-09-01
Press Mentions
Novo Nordisk Tees up Phase 3 Trial for Once-Weekly InsulinSeptember 24th, 2020- Switching to Investigational Once-Weekly Insulin Icodec from Other Basal Insulins Demonstrated to Be Efficacious and Well-Tolerated for People with Type 2 Diabetes in Phase 2 TrialSeptember 22nd, 2020
Type 2 Diabetes May Be Preventable, but Why Isn't Type 1?November 14th, 2019- Join now to see all
